PMID- 37486698
OWN - NLM
STAT- MEDLINE
DCOM- 20240328
LR  - 20240409
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 33
IP  - 3
DP  - 2024 Mar
TI  - A meta-analysis of the efficacy of intra-arterial chemotherapy for the management 
      of retinoblastoma patients.
PG  - 207-216
LID - 10.17219/acem/166664 [doi]
AB  - BACKGROUND: Intra-arterial chemotherapy (IAC) is considered a unique technique 
      for retinoblastoma (Rb) management and has widespread applicability as a 
      first-line or second-line treatment due to the high globe survival rates. 
      OBJECTIVES: This meta-analysis aimed to assess the efficacy of IAC approach among 
      patients with Rb. MATERIAL AND METHODS: This study outlined the most recent 
      research on IAC effectiveness in Rb treatment. We carried out a systematic search 
      for published papers examining IAC treatment among patients with Rb using 
      electronic search engines, including Embase, Web of Science (WoS), PubMed, OVID, 
      and Google Scholar, until October 2021. RESULTS: This meta-analysis included 39 
      observational studies with 2604 treated eyes and 3112 individuals who were 
      eligible for inclusion. Enucleation rates varied from 0% to 43.7% in the chosen 
      trials, with an odds ratio (OR) of 0.52 (95% confidence interval (95% CI): 
      0.41-0.66, p < 0.0001). A range of 30-100% was reported for globe salvage across 
      27 investigations involving 2310 eyes. The estimated OR of globe salvage was 
      2.41, with 95% CI of 1.6-3.63 and a p-value <0.0001. The combined total effect 
      sizes and the death rate for the proportion of cases with metastatic Rb were as 
      follows: OR = 0.03 (95% CI: 0.03-0.03) and OR = 0.05 (95% CI: 0.04-0.05, p < 
      0.0001), respectively. CONCLUSION: Retrospective trials have shown that 
      intra-arterial-based therapy for Rb is an effective choice. Intra-arterial 
      chemotherapy also reduced enucleation and metastasis incidence rates. The paucity 
      of evidence in the literature necessitates further high-level studies.
FAU - Yu, Guoxiao
AU  - Yu G
AD  - Department of Ophthalmology, First People's Hospital of Linping District, 
      Hangzhou, China.
FAU - Zhou, Xiaoqiang
AU  - Zhou X
AD  - Department of Ophthalmology, First People's Hospital of Linping District, 
      Hangzhou, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Radiotherapy, Hangzhou Cancer Hospital, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Humans
MH  - Melphalan/therapeutic use
MH  - Observational Studies as Topic
MH  - *Retinal Neoplasms/drug therapy/pathology
MH  - *Retinoblastoma/pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - globe salvage
OT  - metastases
OT  - retinoblastoma
EDAT- 2023/07/24 13:07
MHDA- 2024/03/28 06:44
CRDT- 2023/07/24 11:35
PHST- 2022/10/27 00:00 [received]
PHST- 2023/05/31 00:00 [accepted]
PHST- 2024/03/28 06:44 [medline]
PHST- 2023/07/24 13:07 [pubmed]
PHST- 2023/07/24 11:35 [entrez]
AID - 10.17219/acem/166664 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2024 Mar;33(3):207-216. doi: 10.17219/acem/166664.